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Abstract
Background: Transient receptor potential (TRP) receptors expressed by primary sensory neurons mediate thermosensitivity,
and may play a role in sensory pathophysiology. We previously reported that human dorsal root ganglion (DRG) sensory
neurons co-expressed TRPV1 and TRPV3, and that these were increased in injured human DRG. Related receptors TRPV4,
activated by warmth and eicosanoids, and TRPM8, activated by cool and menthol, have been characterised in pre-clinical models.
However, the role of TRPs in common clinical sensory neuropathies needs to be established.
Methods: We have studied TRPV1, TRPV3, TRPV4, and TRPM8 in nerves (n = 14) and skin from patients with nerve injury,
avulsed dorsal root ganglia (DRG) (n = 11), injured spinal nerve roots (n = 9), diabetic neuropathy skin (n = 8), non-diabetic
neuropathic nerve biopsies (n = 6), their respective control tissues, and human post mortem spinal cord, using
immunohistological methods.
Results: TRPV1 and TRPV3 were significantly increased in injured brachial plexus nerves, and TRPV1 in hypersensitive skin after
nerve repair, whilst TRPV4 was unchanged. TRPM8 was detected in a few medium diameter DRG neurons, and was unchanged
in DRG after avulsion injury, but was reduced in axons and myelin in injured nerves. In diabetic neuropathy skin, TRPV1
expressing sub- and intra-epidermal fibres were decreased, as was expression in surviving fibres. TRPV1 was also decreased in
non-diabetic neuropathic nerves. Immunoreactivity for TRPV3 was detected in basal keratinocytes, with a significant decrease
of TRPV3 in diabetic skin. TRPV1-immunoreactive nerves were present in injured dorsal spinal roots and dorsal horn of control
spinal cord, but not in ventral roots, while TRPV3 and TRPV4 were detected in spinal cord motor neurons.
Conclusion: The accumulation of TRPV1 and TRPV3 in peripheral nerves after injury, in spared axons, matches our previously
reported changes in avulsed DRG. Reduction of TRPV1 levels in nerve fibres in diabetic neuropathy skin may result from the
known decrease of nerve growth factor (NGF) levels. The role of TRPs in keratinocytes is unknown, but a relationship to
changes in NGF levels, which is produced by keratinocytes, deserves investigation. TRPV1 represents a more selective
therapeutic target than other TRPs for pain and hypersensitivity, particularly in post-traumatic neuropathy.
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Background
The cloning of the vanilloid receptor-1 (TRPV1) [1,2] has
led to greater understanding of the mechanisms of ther-
mosensation and the effects of capsaicin, the noxious
component from chilli peppers. TRPV1 is a non-selective,
cation channel activated by capsaicin and heat (42°C or
greater), and is a member of the transient receptor poten-
tial (TRP) family of temperature sensitive ion channels.
Thermal sensations and pain are detected via sub-sets of
neurons which are activated within distinct temperature
ranges, from cool (<25°C – 28°C – TRPM8 [3]), warm
(>27°C – 38°C – TRPV3[4,5] and TRPV4 [6,7] to nox-
ious/painful heat (>43°C – 52°C – TRPV2 [8] and
TRPV1[1,2]) and cold (<17°C -TRPA1) sensa-
tions[3,9,10].
Studies of TRPV1 in animal models have revealed its role
in heat and pain mechanisms [11,12]. Subsequent studies
indicated that it may not act as the only receptor for heat
[13] especially since the response of neurons to heat and
capsaicin are not always identical [14]. Searches of the
GenBank nucleotide databank revealed an unfinished
human sequence homologous to TRPV1, which has since
been identified as a temperature-sensitive but capsaicin
and pH insensitive, vanilloid receptor-like protein nomi-
nated as TRPV3 [4,5]. Although vanilloid receptors are
known to exist and function as homomers [15,16], some
evidence has been provided for the biochemical associa-
tion of TRPV3 and TRPV1 suggesting heteromerization
[17], thus allowing a greater range of receptor characteris-
tics. In addition to its co-localization with TRPV1 in
small/medium diameter sensory neurons of the dorsal
root ganglion (DRG), the number of both TRPV3- and
TRPV1- immunoreactive sensory neurons increased sig-
nificantly after DRG avulsion injury i.e. central axotomy
[4]. In genetically modified mice lacking the TRPV1 recep-
tor, thermal hyperalgesia was impaired [18]. In animal
models of nerve injury, TRPV1 mRNA was reported to be
down-regulated after axotomy [19] but up-regulated in
spared nerve fibres [20]. Other studies have demonstrated
changes in the molecular phenotype of undamaged neu-
rons in neuropathic pain models of nerve ligation. In the
Seltzer model, where undamaged afferents may be identi-
fied by retrograde labelling, the expression of the neu-
ropeptides substance P and galanin, both known
nociceptive mediators, as well as mRNA for the sodium
channel SNS, increased in the somata of undamaged
fibres [21-23].
Relatively little is known of vanilloid receptors in human
nerve injury and skin, and their relationship to pain or
hypersensitivity. Nerve injury-induced alterations of
sodium channel density and distribution is thought to
contribute to pain by generation of ectopic discharges
from the neuroma or DRG [24]. Previous studies of
injured human nerves have shown that some sodium
channel subunits accumulate in proximal nerve stumps
[25] and neuromata [26] while others can be switched on
[24] thus contributing to changes in membrane excitabil-
ity and/or pain. Peripheral nerve injury in humans may
lead to changes in skin sensitivity depending upon the
level at which injury is sustained and its severity. Numb-
ness, hypo- or hyper-algesia and allodynia are common
symptoms, sometimes in combination, which may arise
over many years following injury or surgical repair. Such
variability in sensation is due to processes of nerve regen-
eration and re-innervation of the skin, and may lead to
such phenomena as paradoxical sensation (burning sen-
sation on cooling the skin). Phenotypic change of primary
afferents with respect to expression of TRPs may be one
possible explanation for some of these symptoms and
signs.
TRPV3 and TRPV1 are present not only in DRG sensory
neurons but also in various regions of the central nervous
system and non-neuronal tissue [5,27]. TRPV3, for exam-
ple, has been detected in rodent keratinocytes [28]. In
addition, TRPV1-immunoreactivity has been shown to be
present in cultured keratinocytes where its activation by
capsaicin induces the production of pro-inflammatory
mediators such as COX-2, IL-8 and PGE-2 [29,30]. The
presence of vanilloid receptors in keratinocytes thus pro-
vides a potential for keratinocyte/nerve interaction [28],
but these findings and their physiological relevance
remain controversial. Basal and supra-basal keratinocytes
also produce the neurotrophins NGF and NT-3 respec-
tively [31,32] and TRPV1 is known to be regulated by neu-
rotrophins, i.e. NGF and GDNF [33-38]. Evaluation of
epidermal innervation has proven to be helpful for the
assessment of diabetic and other small fibre neuropathies,
where innervation has been related to sensory changes
[31,39-43]. In an animal model of diabetes, thermal allo-
dynia and hyperalgesia were associated with sensitisation
of TRPV1 receptors in spinal cord [44].
TRPV4 is a nonselective cation channel, first described as
an osmosensor [6], whose opening seems to result from
tyrosine kinase-dependent phosphorylation [5]. It is acti-
vated at temperatures above 27°C and expressed and
functions as an osmosensor in rodent nociceptors [45].
Two further, temperature sensitive, ion channels TRPM8
and TRPA1 are localised in sensory neurons and are sensi-
tive to cool/cold temperatures < 25–28°C for TRPM8 and
< 17°C for TRPA1 [3,5,9].
The aim of the present study was to investigate the distri-
bution of the vanilloid receptors TRPV1, TRPV3, TRPV4,
and TRPM8 in normal and injured human peripheral
nerves and spinal nerve roots and in normal and neuro-BMC Neurology 2007, 7:11 http://www.biomedcentral.com/1471-2377/7/11
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pathic (painful neuroma and diabetes) skin and spinal
cord,
Methods
Tissues
Specimens of injured nerve (proximal to site of injury)
and dorsal root ganglion (DRG) were obtained during
surgery for brachial plexus repair. Specimens were sub-
divided according to the delay between date of injury and
tissue collection at surgery, where acute was defined as less
than 3 weeks delay (acute nerves: n = 6; male 5; age range
14 – 34 y; chronic: n = 8; male 5; age range 15 – 43 y; and
acute DRG: n = 5; male 4; age range 18 – 50 y; chronic
DRG: n = 6; male 6; age range 18 – 30 y). Control nerves
(n = 8; male 6; age range 36 – 81 y) were obtained during
routine surgery for limb amputation or similar proce-
dures, and control DRG (n = 8; male 3; age range 41 – 98
yr) obtained via the Netherlands Brain Bank with less than
12 h post-mortem delay. Dorsal and ventral pairs of
injured (root avulsion) spinal nerve roots were obtained
also during brachial plexus repair (n = 9, 4 acute and 5
chronic; male 8; age range 22 – 47 y). Neuropathic, sural
nerve biopsies (n = 6; 4 male; age range 49 – 71 yr) were
obtained from patients with neuropathies, including
demyelinating and polyneuropathies. Control, human
spinal cords (n = 2; male 1; age 60 and 64 y), with small
attached nerve roots, were obtained after less than 12 h
post-mortem delay via the Netherlands Brain Bank. Nor-
mal, hyper- and hypo-sensitive skin and painful neuroma
samples were collected from the amputated arm of a
patient who had a brachial plexus injury with subsequent
repair 8 years previously (n = 1; male, age 46 y);. Full
thickness, lateral calf skin biopsies were obtained from
diabetic patients (n = 8; male 8; age range 36–65 y) under
local anaesthetic, and control calf skin biopsies were
obtained from patients undergoing harvest of intact sural
nerve for brachial plexus repair, or therapeutic elective
limb amputation for a non-neurological condition (n = 8;
male 5; age range 33–71 y). Skin samples were obtained
from excised, supernumerary human digits (n = 2). Fully
informed consent was obtained for all tissues collected,
with approval of the Local Ethics Committees.
Immunocytochemistry
Tissues were snap frozen in liquid nitrogen and stored at -
80°C until use. For cryomicrotomy, nerves were orien-
tated longitudinally and spinal cord transversally, while
skin specimens were orientated to optimise perpendicular
dermal papillae. Frozen, unfixed sections (10 μm) were
collected onto poly-L-lysine-coated (Sigma Poole Dorset
UK) glass slides and post-fixed in freshly prepared, 4% w/
v paraformaldehyde in PBS (0.1 M phosphate; 0.9% w/v
saline; pH 7.3). After washing in PBS, endogenous perox-
idase was blocked by incubation with 0.3% w/v hydrogen
peroxide in methanol. After a further wash in PBS, the tis-
sue sections were incubated overnight with primary anti-
bodies (Table 1) including antibodies to the novel human
TRPV4 raised against the N-terminal amino acids
MADSSEGPRAGPGEVA(C). For double staining, TRPV1
or TRPV3 antibodies were mixed with the neuronal
marker peripherin (PPN). For co-localisation of TRPV4
and TRPV1 or TRPV4 and TRPV3, pairs of serial, "mirror
image" sections, each containing parts of the same cells,
were used for immunostaining. Method controls included
omission of primary antibodies or their replacement with
pre-immune serum. Specificity controls included pre-
incubation of primary antibodies with homologous anti-
gen at 10 -1 to 10 -6 mg per ml of diluted antibodies prior
to immunostaining. Specificity of antibodies to TRPV1
and TRPV3 has been described in a previous publication
[4]. Sites of antibody attachment were revealed using a
nickel enhanced ABC (peroxidase; Vector Laboratories,
High Wycombe, Bucks., U.K.) method [46].
Analysis
Computerized image analysis was used (Seescan Cam-
bridge, UK) to quantify immunoreactive nerve fibres.
Images were captured via video link to an Olympus BX50
microscope (x20 objective) and scanned by the computer.
Three to five fields from two tissue sections were analysed
where positive immunostaining was highlighted by set-
ting grey-level detection limits at threshold and the area of
highlighted fibres obtained as percentage area of the field
scanned.
The size (small/medium or large diameter) and number
of nucleated sensory neurons for each DRG section were
assessed using a calibrated microscope eyepiece graticule
and the number of positive TRPV4 cells expressed as % of
total neurons for each DRG sample.
The intensity of immunoreaction for TRPV3 or TRPV4 in
basal keratinocytes was graded by two independent
observers on an arbitrary scale from negative (0) to maxi-
mum (3). TRPV1-, neurofilament- and PPN- immunore-
active sub-epidermal fibres were counted for each section
and the length of epidermis measured using a microscope
eyepiece graticule.
All statistical analysis used non-parametric Mann-Whit-
ney t test.
Results
A summary of results obtained in the tissues examined are
presented in tabular form (Table 2).
DRG
Antibodies to TRPV4 reacted strongly with small/medium
but weak with large diameter neurons (Fig 1) with no sig-
nificant change after injury [% TRPV4 small/mediumBMC Neurology 2007, 7:11 http://www.biomedcentral.com/1471-2377/7/11
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cells, median (range): controls 65.5 (57–73); acute 54
(48–68); chronic 60 (47–75); large cells: controls 63 (22–
84); acute 56 (56–59); chronic 57 (44–78)]. Co-localisa-
tion (serial 'mirror-image' sections) revealed that most
TRPV4 positive, small/medium cells were also TRPV1 and
TRPV3 positive (Fig 1). Pre-incubation of primary anti-
bodies to TRPV4 with homologous peptide antigen com-
pletely prevented staining at 10-2  mg/ml diluted
antibodies.
Strong TRPM8-immunoreactive fibres were detected in all
DRG although sensory cell bodies (small/medium diam-
eter) were few but detected using antibodies from two
independent sources (Fig 2A,B). There was no obvious
change of this pattern after chronic or acute DRG avulsion
injury. In samples of human tooth pulp, which contain C
and A delta sensory fibres, TRPM8-immunoreactivity was
seen in large calibre, fibres (Fig 2C), with identifiable nar-
row gaps indicative of nodes of Ranvier (Fig 2C arrows),
and in fine calibre fibres. Pre-incubation of TRPM8 anti-
bodies (GSK 1323) with homologous antigen abolished
staining (Fig 2D).
Peripheral nerve
In control, uninjured peripheral nerve, immunoreactivity
for TRPV1 (Fig 3A), TRPV3 (Fig 3C), and TRPV4 (Fig. 3E)
was detected in fine to medium calibre fibres with TRPV3
immunoreactivity less intense than that for TRPV1 or
TRPV4. After nerve injury both TRPV3 (Fig. 3D) and
TRPV1 (Fig 3B) – immunoreactive fibres appeared to be
increased in both number and intensity but there was no
change for TRPV4 (Fig 3F).
Peripheral nerves also displayed immunoreactivity for
TRPM8 which was strong in large calibre fibres and
emphasized nodes of Ranvier as described above thus sug-
gesting an association or cross reaction with myelin in
glial/Schwann cells (Fig 3G). After nerve injury and partic-
ularly distal to injury, TRPM8-immunoreactivity in nerve
fibres was deterioriated and fragmented further suggesting
its presence in glial/Schwann cells (Fig 3H). Immunoreac-
tivities for both TRPV3 and TRPV1 (% area immunoreac-
tive nerve) were significantly increased after injury
[median (range) TRPV3: control 5.25 (0.9–6.9), injured
15.0 (5.8–20.1) p < 0.001; TRPV1; control 17.6 (12.1–
20.6), injured 24.1 (18.6–32.0) p < 0.001; Fig 4A,C] and
although image analysis of the nerve marker peripherin
showed no change, % ratios of TRPV3 or TRPV1 to
peripherin were significantly increased also [median
(range) % TRPV3:PPN, control 17.6 (2.9–19.4), injured
50.1 (25.0–67.9), p < 0.001; % TRPV1:PPN, control 55.7
(31.9–82.3), injured 89.8 (63.4–100.0), p < 0.001; Fig
4B,D].
In tissues collected from a subject at limb amputation,
with partial damage at C6 root and complete avulsion at
Table 2: Results Summary
TRPV1 TRPV3 TRPV4 TRPM8
Nerve injury Increased (brachial plexus) Increased (brachial plexus) Positive Unchanged Positive. Reduced
Hypersensitive skin Increased Not detected Fibres Unchanged Positive Increased?
DRG injury Decreased (see Smith et al 2002) Decreased (see Smith et al 2002) Positive Unchanged Co-localise 
with TRPV1/TRPV3
Positive Unchanged
Diabetic skin Decreased fibres Negative 
keratinocytes
Nerve fibres not detected Trend 
for decreased keratinocytes
Positive fibres – very few Positive Unchanged
Neuropathic nerve Positive fibres Decreased None detected Not examined Positive Unchanged
Spinal cord Positive dorsal horn Positive motor neurones Positive weak motor neurones Weak fibres in dorsal horn and 
roots
Dorsal roots Positive fibres Not detected Positive fibres Positive fibres
Ventral roots Not detected Positive fibres Positive fibres Positive fibres
TRPV: Transient Receptor Potential Vanilloid; TRPM: Transient Receptor Potential Melastatin; DRG: Dorsal Root Ganglion.
Table 1: Antibody Characteristics
Antibody Host Source Titre
Human TRPV3 Rabbit GSK, Harlow, UK. 1:1000
Human TRPV1 Rabbit GSK, Harlow, UK. 1:10000
Human TRPV4 Rabbit GSK, Harlow, UK. 1:1000
TRPM8 Rabbit GSK, Harlow, UK. 1:1000
TRPM8 Rabbit Phoenix Pharmaceuticals, Belmont, CA, USA 1: 250
Peripherin Mouse Novocastra, Newcastle, UK 1:500
Neurofilament Mouse Dako Cytomation, Cambs. UK 1:10000
TRPV: Transient Receptor Potential Vanilloid; TRPM: Transient Receptor Potential Melastatin; GSK: GlaxoSmithKline; Titre represents final 
working dilution of primary antibodies.BMC Neurology 2007, 7:11 http://www.biomedcentral.com/1471-2377/7/11
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C7-T1, with subsequent plexus repair, abundant TRPV1
immunoreactive, sub-epidermal fibres were present in
hypersensitive skin (Fig 5A,B) but very few in an adjacent
hyposensitive skin region (Fig 5C). In comparison, nor-
mal sensate skin (Fig 5D) showed fewer TRPV1-immuno-
reactive sub-epidermal fibres than hypersensitive skin.
TRPV1-immunoreactive fibres were detected in a painful
peripheral neuroma (Fig 5E) and in a nerve proximal to
an area of painful scar neuritis (Fig 5F). Frequent, TRPM8-
immunoreactive large calibre fibres were detected in the
sub-epidermal region of hypersensitive (Fig 5G) but not
hyposensitive (Fig 5H) skin. In these same tissue samples,
TRPV3 immunostaining of peripheral fibres was below
detection level.
Nerve roots and spinal cord
Dorsal but not ventral injured spinal roots, and dorsal
roots attached to post-mortem spinal cord, showed strong
TRPV1 immunoreactivity (Fig 6A). No TRPV1-immunore-
activity was detected in motor neurons or in the ventral
horn of the spinal cord.
TRP receptors in peripheral nerve Figure 3
TRP receptors in peripheral nerve. TRPV1 (A, B), 
TRPV3 (C, D), TRPV4 (E, F) and TRPM8 (G, H) immunore-
activity in subsets of fibres in control, uninjured and injured 
peripheral nerves. Scale bar = 75 μm.
Co-localisation of TRPV4 with other TRPV receptors in  DRG Figure 1
Co-localisation of TRPV4 with other TRPV receptors 
in DRG. TRPV3 and TRPV1 immunoreactivity mostly co-
localise with TRPV4 in small/medium neurons. Arrows indi-
cate the same cells in serial sections. Scale bar = 75 μm.
TRPM8 in DRG and fibres Figure 2
TRPM8 in DRG and fibres. TRPM8 immunoreactivity in 
small/medium diameter neurons using antibodies from GSK 
(A), or Phoenix Pharmaceuticals (B) and in fibres in tooth 
pulp with gaps indicating nodes of Ranvier (C -arrows). Pre-
incubation of antibodies with antigen gave no staining (D). 
Scale bar = 50 μm.BMC Neurology 2007, 7:11 http://www.biomedcentral.com/1471-2377/7/11
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TRPV4 was present in injured roots, both dorsal and ven-
tral (Fig 6B), but was weak in motor neurons and fibres in
the ventral horns. There was no significant staining in the
dorsal horns.
Four out of 9 samples showed strong TRPV3-immunore-
activity in motor neurones and fibres in the ventral horn
of the spinal cord (Fig 6C). In these positive samples,
counts of TRPV3 motor neurones were 33% of total. In
accord, there was strong TRPV3 immunoreactivity, mostly
in large calibre fibres, in ventral (Fig 6D) but not dorsal
spinal roots. TRPV3 immunoreactivity in the ventral roots
was largely lost three to four weeks following injury.
Antibodies to TRPM8 showed fibres in both dorsal (Fig
6E) and ventral (Fig 6F) spinal roots.
Neuropathic nerves
Non-diabetic neuropathic peripheral nerves showed
strong immunostaining for neurofilaments, with a sub-
population of strong fibres immunoreactive for TRPV1.
Image analysis of TRPV1 and the nerve marker neurofila-
ments in serial sections showed that the ratio of immuno-
reactive area (% area) for TRPV1: neurofilaments was
significantly decreased in virtually all neuropathic nerves
regardless of pathology [median (range); control 0.11
(0.06–0.21); neuropathic 0.032 (0.002–0.06); p < 0.02;
Fig 7]. There was no obvious change of TRPM8 immuno-
reactivity.
Diabetic neuropathy skin
TRPV1-immunoreactive fibres were detected in distal
peripheral nerve and were present in fine fibres in control
skin up to and including the epidermis, whilst TRPV3-
immunoreactivity in fibres was relatively weak in the
nerve trunk and undetectable at the skin level but was
present in basal keratinocytes (see below).
TRPV1 in hypersensitive skin Figure 5
TRPV1 in hypersensitive skin. TRPV1-immunoreactive 
fibres in: thenar eminence (A, B) from a patient with partial 
damage to C6 and complete avulsion of C7-T1 and hypo-sen-
sitive skin (C) from the ulnar border of his distal forearm; 
normal skin (D); painful peripheral neuroma (E) and nerve 
proximal to an area of painful scar neuritis (F); TRPM8-
immunoreactive fibres in the sub-epidermis of hypersensitive 
(G) but not in hyposensitive skin (H). Scale bar = 25 μm A, 
B, D, G, H; 50 μm E, F; 100 μm C.
TRPV3 and TRPV1 in peripheral nerves Figure 4
TRPV3 and TRPV1 in peripheral nerves. Area (%) of 
TRPV3 (A) and TRPV1 (C) in control and injured nerves and 
comparison (ratio) with total peripherin (PPN) nerve area 
(%) for TRPV3 (B) and TRPV1 (D).BMC Neurology 2007, 7:11 http://www.biomedcentral.com/1471-2377/7/11
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TRPV3 immunoreactivity was detected most strongly in
basal keratinocytes in normal skin, sometimes continu-
ously along the length of the epidermis (Fig 8A) whilst
diabetic skin showed weaker cells (Fig 8B). TRPV3 immu-
noreactivity was not detected in fibres in any sample. In
contrast, TRPV1 immunoreactivity was present in fibres
throughout the dermis with fine fibres penetrating the
epidermis of control (Fig 8C – arrows) and fewer in dia-
betic skin (Fig 8D). Keratinocytes showed little or no
immunoreactivity for TRPV1.
Few TRPV4-immunopositive nerve fibres were detected in
skin samples. Positive but patchy immunostaining of
TRPV4 basal keratinocytes was observed (Fig 8E). Sub-epi-
dermal fibres were detected using antibodies to peripherin
(PPN; Fig 8F)
As described above, antibodies to TRPM8 showed strong
large calibre and weak fine calibre fibre bundles up to the
sub-epidermal layer. TRPM8 immunoreactivity was not
detected in keratinocytes.
In diabetes, counts of TRPV1 immunoreactive fibres per
mm length of tissue section showed a significant decrease
in both epidermis and sub-epidermis [median (range)
Epidermis: control 1.2 (0.0–2.6), diabetic 0.0 (0.0–0.6); p
< 0.01; Sub-epidermis: control 4.4 (0.2–11.1), diabetic
0.4 (0.0–3.4); p < 0.01; Fig 9A,B]. In order to determine
whether this decrease of TRPV1-expressing fibres is due
solely to the denervation associated with diabetes, the
number of TRPV1-immunoreactive fibres was correlated
with the number of fibres obtained with the neuronal
markers neurofilaments or peripherin. In the sub-epider-
mis, peripherin- but not neurofilament -immunoreactive
fibres were significantly reduced [PPN fibres per mm,
median (range) control 2.8(1.6–5.7), diabetic 0.1(0.0–
1.1); p < 0.01; Fig 10A]. Comparison of the ratio of TRPV1
with either neuronal marker showed a significant decrease
in diabetic sub-epidermis [TRPV1: peripherin median
(range): controls 2.2 (0.7–4.2); diabetic 0.6 (0–1.3) p <
0.01; TRPV1: neurofilament median (range): controls
1.05 (0.44–1.75); diabetic 0.14 (0.04–0.38) p < 0.01; Fig
10B,C] indicating a decrease of TRPV1 immunoreactivity
preceding the decrease in innervation.
Visual assessment of the intensity of TRPV3 and TRPV4
immunostaining in keratinocytes in diabetic skin showed
a trend for decrease of TRPV3 [median (range) control 1.5
(1.0–2.5), diabetic 1.0 (0.5–2.0), p = 0.053; Fig 11] but
not TRPV4 (not shown).
Non-diabetic neuropathic nerves Figure 7
Non-diabetic neuropathic nerves. The ratio TRPV1: 
neurofilament (NF) for image analysis values (% area) is signif-
icantly decreased for neuropathic nerves (p < 0.02).
TRP receptors in spinal cord and roots Figure 6
TRP receptors in spinal cord and roots. TRPV1 (A) in 
dorsal and TRPV4 (B) in ventral spinal roots. Strong TRPV3-
immunoreactivity in motor neurons (C) and ventral roots 
(D). TRPM8-immunoreactive fibres in dorsal (E) and ventral 
(F) spinal roots. Scale bar = 50 μm.BMC Neurology 2007, 7:11 http://www.biomedcentral.com/1471-2377/7/11
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Discussion
The TRP family appears to have differential expression in
the peripheral nervous system, and specific changes in
peripheral neuropathies.
DRG
In this study we have described, to our knowledge for the
first time, the presence of TRPV4 and TRPM8 in human
sensory neurons. TRPV4 expression was not specific for
any neuronal subtype in DRG and did not appear to be
affected by injury in either DRG or peripheral nerves. The
wide distribution of TRPV4 in both small and large neu-
rons matches observations in mice [49]. The distribution
of TRPM8 was confined to a small proportion of small/
medium neurons. TRPM8 immunoreactive large calibre
fibres with clear nodes of Ranvier were observed, suggest-
ing labelling of Schwann cells-myelin in addition to fine
weak fibres, as also observed by us in tooth pulp (unpub-
lished observations). Small dot-like structures in the tis-
sue surrounding the sensory neurons, apparent with
antibodies in Figure 1 probably represents immunoreac-
tivity in nerve fibres cut transverse to the plane of the sec-
tions. TRPM8 mRNA has been shown to be localised
mainly in A- delta fibres/C-fibres in rat primary afferent
neurones [47]. In rodents, TRPM8 and the cold activated
receptor TRPA1 are also detected in sub-populations of
small neurons. In mouse DRG, TRPM8 mRNA does not
co-express with many of the classical markers of nocicep-
tion including TRPV1[48]. However, TRPA1 is found in
nociceptive sensory neurons in DRG and colocalises with
TRPV1, CGRP and SP but not with TRPM8 in rat [9,47].
Co-expression of TRPA1 with TRPV1 could explain the
paradoxical heat sensation which may be experienced on
exposure to a very cold stimulus.
We have shown previously and confirmed in this study
that TRPV1 and TRPV3 were present in human DRG neu-
rons, mostly of small/medium diameter, and that the
Quantification of TRPV1-immunoreactive fibres in skin Figure 9
Quantification of TRPV1-immunoreactive fibres in 
skin. Counts of epidermal (A) and sub-epidermal (B) fibres 
were significantly reduced (p < 0.05) in diabetic skin.
TRPV3 and TRPV1 immunoreactivity in diabetic skin Figure 8
TRPV3 and TRPV1 immunoreactivity in diabetic 
skin. TRPV3-immunoreactive basal keratinocytes in control 
(A) and diabetic (B) skin. TRPV1-immunoreactive dermal 
and epidermal (arrows in C) fibers in control (C) and dia-
betic (D) skin. TRPV4 – immunoreactivity in keratinocytes 
(E) and nerve marker (peripherin PPN) in control skin (F). 
Scale bar = 50 μm A, B, D, E ; 25 μm C, F.BMC Neurology 2007, 7:11 http://www.biomedcentral.com/1471-2377/7/11
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number of positive cells increased after DRG avulsion
injury [4].
Roots and Spinal Cord
There was a clear difference in the distribution of TRPV3
and TRPV1 in spinal nerve roots. TRPV3 was present in
ventral but not dorsal roots, in contrast, TRPV1 was
present in dorsal but negligible in ventral roots.
The strong immunoreactivity for TRPV3 in adult human
motor neurons and ventral roots correlates well with stud-
ies in monkeys showing TRPV3 m-RNA in motor neurons
and other neuronal elements [5]. Accordingly, we found
strong TRPV3 immunoreactivity in motor neurons in
adult rat (data not shown). The TRPV3-immunoreactive,
large calibre fibres seen in control and acutely injured ven-
tral spinal roots almost disappear after chronic injury. The
weak TRPV3 immunoreactivity in dorsal roots is consist-
ent with a preferential transport peripherally rather than
centrally. It cannot be excluded that these observations
reflect a difference in levels of TRPV3 protein or quality of
the antibody.
TRPV1 immunoreactivity was not detected in ventral
roots, which may be expected as it was not detected in
motor neurons. In rats, TRPV1 has been shown to be
transported from the DRG neurons both peripherally and
centrally to laminae I and II of the spinal cord via the dor-
sal root [50]. In accord with this, we have shown that
TRPV1 is present in spinal dorsal roots.
TRPV3 immunostaining in keratinocytes Figure 11
TRPV3 immunostaining in keratinocytes. The intensity 
of TRPV3 immunostaining in keratinocytes is decreased in 
diabetic skin compared to control. The median value is indi-
cated.
Quantification of nerve fibres in sub-epidermis Figure 10
Quantification of nerve fibres in sub-epidermis. 
Peripherin (PPN) – immunoreactive nerve fibres per mm 
length of skin section (A) and ratios of TRPV1: PPN (B) or 
TRPV1: NF (C) are significantly reduced in diabetic skin.BMC Neurology 2007, 7:11 http://www.biomedcentral.com/1471-2377/7/11
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Peripheral nerve-brachial plexus injury
In this study we have shown that both TRPV3 and TRPV1
are increased in peripheral nerve proximal to the site of
injury in accord with our previous study of human DRG,
[4]. The increase in injured nerves indicates that these
receptors continue to be exported from the ganglion and/
or accumulate in the nerve proximal to injury, despite
overall reduced support from peripheral trophic factors
e.g. NGF/GDNF. An increased availability of trophic fac-
tors to spared nerve fibres may be similar to the finding in
an animal model of partial nerve injury. In this model it
was suggested that undamaged fibres obtain more neuro-
trophin made available because of the reduced uptake by
damaged fibres [20]. The increased TRPV receptors immu-
nostaining seen in our study, in combination with the
presence of regenerating fibres, may be particularly rele-
vant for the development and persistence of pain. In addi-
tion, inflammatory mediators and neurotrophins derived
from damaged Schwann cells or infiltrating macrophages
at the injury site may contribute to enhance the produc-
tion of vanilloid receptors [51-54].
The abundance of TRPV1 fibres in painful, hypersensitive
skin relative to normal skin correlates well with the TRPV1
involvement in mechanisms of pain and hyperalgesia in a
similar fashion to that described in injured nerve above.
Corroborative evidence for the involvement of TRPV1-
immunoreactive nerves in painful skin is shown in our
recent work in vulvodynia and breast pain [38,55]. The
lack of detection of TRPV3 immunoreactive fibres in skin
may be similar to that described for dorsal roots.
Peripheral neuropathic nerves
There was a clear decrease in the expression of TRPV1 in
neuropathic nerves compared to controls. The cases were
different, from distal axonal to demyelinating neuropa-
thy. In all cases histology showed a decrease of nerve
fibres and/or axonal atrophy.
Skin and diabetic neuropathy
Keratinocytes
We have shown that TRPV3 is present in human keratino-
cytes, which is consistent with the report of TRPV3 in
rodent keratinocytes [28]. Our report that TRPV1 and
TRPV3 co-localize in human DRG suggested co-expres-
sion but we were unable to detect TRPV1 in human kerat-
inocytes despite several reports describing TRPV1 in
keratinocytes and other non-neuronal cells [29,30,56-59].
However these studies were performed in cultured kerati-
nocytes and TRPV1 expression could therefore be a conse-
quence of culture conditions. Alternatively, the lack of
TRPV1 immunoreactivity in keratinocytes in the present
study could reflect low level of expression or receptor con-
formational changes preventing antigen-antibody recog-
nition.
Diabetic epidermis is known to be abnormally thin, so the
trend we describe for decrease of TRPV3 in keratinocytes,
may be related to changes of neurotrophins or other fac-
tors controlling skin differentiation and TRPV3 expres-
sion. Functional properties of vanilloid receptors in
keratinocytes have been suggested to involve novel prop-
erties of transduction between the basal keratinocytes and
sub-epidermal/epidermal nerve endings [28] or exocyto-
sis of epidermal lamellar bodies, which is regulated by cal-
cium influx [60]. A functional role for vanilloid receptors
in keratinocytes remains unclear.
Innervation
In the present study, we have demonstrated that TRPV1 is
decreased in both intra- and sub-epidermal fibres in dia-
betes resulting in the hypo-sensitivity typical of diabetic
neuropathy. Similar results for intra-epidermal fibres have
been shown in human diabetic skin using the pan-neuro-
nal marker PGP-9.5 [39] whilst others have shown no
change of TRPV1[40]. The observed decrease of TRPV1
may have been due simply to an overall reduction of
innervation, a common feature of diabetes. To address
this we used a neuronal marker for quantification of total
innervation to normalise values. Ideally, antibodies to the
pan-neuronal marker PGP-9.5 would have been used but
these are not optimal on post-fixed tissue. Instead, com-
parisons were made using the nerve markers neurofila-
ment and peripherin, which do not detect epidermal
fibres, thus limiting our normalised analysis to sub-epi-
dermal fibres. The density of TRPV1 sub-epidermal fibres
was still clearly decreased in diabetic skin after normalisa-
tion with either of the above neuronal markers. In addi-
tion to a loss of fibres, our results therefore suggest that
TRPV1 is down-regulated in remaining fibres.
Conclusion
Vanilloid receptors are differentially regulated after nerve
injury and in diabetic neuropathy. A change of expression
and regulation of vanilloid receptors may play a role in
sensory dysfunction, related to states of hyper/hypo-alge-
sia. TRPV1 represents a more selective target than TRPV3
for pain, particularly for post-traumatic chronic hypersen-
sitivity states.
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